Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials

BACKGROUND: Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including adults with moderate‐to‐severe AD, of up to 52 weeks’ duration, showed tralokinumab was efficacious and well tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Merola, Joseph F., Silverberg, Jonathan I., Reich, Kristian, Warren, Richard B., Staumont‐Sallé, Delphine, Girolomoni, Giampiero, Papp, Kim, de Bruin‐Weller, Marjolein, Thyssen, Jacob P., Zachariae, Rebecca, Olsen, Christiana K., Wollenberg, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091996/
https://www.ncbi.nlm.nih.gov/pubmed/36082590
http://dx.doi.org/10.1111/bjd.21867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091996/
https://www.ncbi.nlm.nih.gov/pubmed/36082590
http://dx.doi.org/10.1111/bjd.21867

Ejemplares similares